NCT04572815View on ClinicalTrials.gov

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

December 16, 2025

Study Completion Date

June 30, 2027

Conditions
Hematologic and Lymphocytic DisorderHematopoietic and Lymphoid System Neoplasm
Interventions
DRUG

Placebo Administration

Given IV and SC

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Ustekinumab

Given IV and SC

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

91010

City of Hope Comprehensive Cancer Center,, Duarte

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

Fred Hutchinson Cancer Center

OTHER